KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) Gross Margin (2016 - 2025)

Historic Gross Margin for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to 80.91%.

  • Pacira BioSciences' Gross Margin rose 39600.0% to 80.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 79.17%, marking a year-over-year increase of 48100.0%. This contributed to the annual value of 75.69% for FY2024, which is 30500.0% up from last year.
  • According to the latest figures from Q3 2025, Pacira BioSciences' Gross Margin is 80.91%, which was up 39600.0% from 77.43% recorded in Q2 2025.
  • Over the past 5 years, Pacira BioSciences' Gross Margin peaked at 80.91% during Q3 2025, and registered a low of 63.99% during Q4 2022.
  • Its 5-year average for Gross Margin is 74.1%, with a median of 74.0% in 2021.
  • In the last 5 years, Pacira BioSciences' Gross Margin plummeted by -115000bps in 2022 and then surged by 96900bps in 2023.
  • Over the past 5 years, Pacira BioSciences' Gross Margin (Quarter) stood at 75.5% in 2021, then decreased by -15bps to 63.99% in 2022, then increased by 15bps to 73.69% in 2023, then increased by 7bps to 78.7% in 2024, then rose by 3bps to 80.91% in 2025.
  • Its Gross Margin was 80.91% in Q3 2025, compared to 77.43% in Q2 2025 and 79.69% in Q1 2025.